Prospective Evaluation of Outcomes of Everolimus-Eluting Stent (XIENCE V) Implantation for Unprotected Left Main Coronary Artery Stenosis: Multicenter Trial.
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2015
At a glance
- Drugs Everolimus (Primary) ; Sirolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms PRE-COMBAT-2
- 19 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2012 Drug company (Abbott Laboratories) added as reported by ClinicalTrials.gov.
- 03 Jun 2011 Actual initiation date changed from May 2009 to Aug 2009 as reported by ClinicalTrials.gov.